GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aimmune Therapeutics Inc (NAS:AIMT) » Definitions » Net Margin %

Aimmune Therapeutics (Aimmune Therapeutics) Net Margin % : 0.00% (As of Jun. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Aimmune Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Aimmune Therapeutics's Net Income for the three months ended in Jun. 2020 was $-69.24 Mil. Aimmune Therapeutics's Revenue for the three months ended in Jun. 2020 was $0.00 Mil. Therefore, Aimmune Therapeutics's net margin for the quarter that ended in Jun. 2020 was 0.00%.

The historical rank and industry rank for Aimmune Therapeutics's Net Margin % or its related term are showing as below:

AIMT' s Net Margin % Range Over the Past 10 Years
Min: -49918.09   Med: 0   Max: 0
Current: -49918.09


AIMT's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -162.84 vs AIMT: -49918.09

Aimmune Therapeutics Net Margin % Historical Data

The historical data trend for Aimmune Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aimmune Therapeutics Net Margin % Chart

Aimmune Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Net Margin %
Get a 7-Day Free Trial - - - - -

Aimmune Therapeutics Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -15,031.65 -

Competitive Comparison of Aimmune Therapeutics's Net Margin %

For the Biotechnology subindustry, Aimmune Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aimmune Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aimmune Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Aimmune Therapeutics's Net Margin % falls into.



Aimmune Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Aimmune Therapeutics's Net Margin for the fiscal year that ended in Dec. 2019 is calculated as

Net Margin=Net Income (A: Dec. 2019 )/Revenue (A: Dec. 2019 )
=-248.497/0
= %

Aimmune Therapeutics's Net Margin for the quarter that ended in Jun. 2020 is calculated as

Net Margin=Net Income (Q: Jun. 2020 )/Revenue (Q: Jun. 2020 )
=-69.244/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aimmune Therapeutics  (NAS:AIMT) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Aimmune Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Aimmune Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aimmune Therapeutics (Aimmune Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8000 Marina Boulevard, Suite 300, Brisbane, CA, USA, 94005
Aimmune Therapeutics Inc is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.
Executives
Gregory Behar director C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Societe Des Produits Nestle S.a. 10 percent owner AVENUE NESTLE 55, VEVEY V8 CH-1800
Kathryn E Falberg director C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Andrew Oxtoby officer: Chief Commercial Officer 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Dallas Jayson Donald Alexander director, officer: President and CEO AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Stacey Denenberg Seltzer director C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Brett K Haumann director 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Douglas T. Sheehy officer: See Remarks C/O AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005-1884
Mark T Iwicki director 84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Patrick G Enright director CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Mark Mcdade director C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Adelman Daniel C Md officer: Chief Medical Officer 23 WOODLEAF AVENUE, REDWOOD CITY CA 94061
Eric Bjerkholt officer: Chief Financial Officer 132 PURDURE AVENUE, KENGSINGTON CA 94708
Sa Nestle 10 percent owner AVE NESTLE 55, CH-1800, VEVEY V8
Mary M. Rozenman officer: See Remarks AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE CA 94005

Aimmune Therapeutics (Aimmune Therapeutics) Headlines

From GuruFocus